Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Imatinib-Resistant/Intolerant CML Extension Study
NCT00786812Phase 4Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nilotinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Disease response (complete hematologic response, cytogenetic response) and progression at 24 months. Started Aug 2008; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00786812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00786812.